Local Drug Delivery Systems for Cancer Therapy.
Conventional methods of delivering anticancer drugs are typically not targeted and can lead to toxic side effects in normal tissues while maintaining effective drug concentrations in the tumor.
APA
Jiang Z, Zhang J, et al. (2026). Local Drug Delivery Systems for Cancer Therapy.. ACS applied materials & interfaces, 18(1), 70-103. https://doi.org/10.1021/acsami.5c17220
MLA
Jiang Z, et al.. "Local Drug Delivery Systems for Cancer Therapy.." ACS applied materials & interfaces, vol. 18, no. 1, 2026, pp. 70-103.
PMID
41436030
Abstract
Conventional methods of delivering anticancer drugs are typically not targeted and can lead to toxic side effects in normal tissues while maintaining effective drug concentrations in the tumor. Simultaneously, tumor barriers and rapid drug clearance pose challenges in maintaining effective drug concentrations in the tumor. Therefore, there is an urgent need for an oncology drug delivery method that offers precise targeting and minimal toxicity and side effects. Local drug delivery systems (LDDSs) are a class of fixed-domain tumor therapeutic systems with a broad range of applications. They exhibit robust drug-loading capabilities and can be implanted into tumor sites in a simple manner, such as through minimally invasive surgery. This enables them to release therapeutic agents in the tumor region in a sustained, controlled, and highly efficient manner. In addition, the characteristics of different types of LDDSs, such as deformability, adhesiveness, and responsiveness, enable them to provide a platform for synergistic tumor therapy, addressing various complex scenarios. In this review, we present commonly employed LDDSs and their therapeutic mechanisms, offering insights into potential directions for future development.
MeSH Terms
Humans; Neoplasms; Antineoplastic Agents; Drug Delivery Systems; Animals; Drug Carriers
같은 제1저자의 인용 많은 논문 (5)
- Key Considerations for the Lenvatinib-Pembrolizumab-Chemotherapy Regimen in Advanced Gastric Cancer: Insights From LEAP-015.
- Deep learning-based mismatch repair prediction using colorectal cancer macroscopic images: a diagnostic study.
- Comment on "Agile 3 + and 4 Scores Accurately Predict Major Adverse Liver Outcomes, Liver Transplant, Progression of MELD Score, the Development of Hepatocellular Carcinoma, and Death in NAFLD".
- Using F-FDG PET/CT-derived body composition features to predict lymphovascular invasion in non-small cell lung cancer.
- Single-cell profiling reveals lineage-specific fibroblast stromal subtypes drive ECM remodeling and immune modulation in the hepatocellular carcinoma tumor microenvironment.